N-Acetylcysteine, a Glutamate Modulator, in the Treatment of Trichotillomania: A Double-blind, Placebo-Controlled Study | Psychiatry and Behavioral Health | JAMA Psychiatry | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.185.54. Please contact the publisher to request reinstatement.
1.
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision.  Washington, DC American Psychiatric Association2000;
2.
Christenson  GAMackenzie  TBMitchell  JE Characteristics of 60 adult chronic hair pullers.  Am J Psychiatry 1991;148 (3) 365- 370PubMedGoogle Scholar
3.
Woods  DWFlessner  CAFranklin  MEKeuthen  NJGoodwin  RDStein  DJWalther  MRTrichotillomania Learning Center Scientific Advisory Board, The Trichotillomania Impact Project (TIP): exploring phenomenology, functional impairment, and treatment utilization.  J Clin Psychiatry 2006;67 (12) 1877- 1888PubMedGoogle ScholarCrossref
4.
Christenson  GAPyle  RLMitchell  JE Estimated lifetime prevalence of trichotillomania in college students.  J Clin Psychiatry 1991;52 (10) 415- 417PubMedGoogle Scholar
5.
Odlaug  BLGrant  JE Prevalence of impulse control disorders in a college sample.  New Research Program and Abstracts, 161st Annual Meeting of the American Psychiatric Association May 3-8, 2008 Washington, DCAbstract NR2-069
6.
Grant  JELevine  LKim  DPotenza  MN Impulse control disorders in adult psychiatric inpatients.  Am J Psychiatry 2005;162 (11) 2184- 2188PubMedGoogle ScholarCrossref
7.
Matsunaga  HKiriike  NMatsui  TOya  KOkino  KStein  DJ Impulsive disorders in Japanese adult patients with obsessive-compulsive disorder.  Compr Psychiatry 2005;46 (1) 43- 49PubMedGoogle ScholarCrossref
8.
Hallopeau  M Alopicie par grattage (trichomanie ou trichotillomanie).  Ann Dermatol Venereol 1889;10440- 441Google Scholar
9.
Chamberlain  SROdlaug  BLBoulougouris  VFineberg  NGrant  JE Trichotillomania: neurobiology and treatment.  Neurosci Biobehav Rev 2009;33 (6) 831- 842PubMedGoogle ScholarCrossref
10.
Bloch  MHLanderos-Weisenberger  ADombrowski  PKelmendi  BWegner  RNudel  JPittenger  CLeckman  JFCoric  V Systematic review: pharmacological and behavioral treatment for trichotillomania.  Biol Psychiatry 2007;62 (8) 839- 846PubMedGoogle ScholarCrossref
11.
Swedo  SELenane  MCLeonard  HL Long-term treatment of trichotillomania (hair pulling).  N Engl J Med 1993;329 (2) 141- 142PubMedGoogle ScholarCrossref
12.
Chakrabarty  KBhattacharyya  SChristopher  RKhanna  S Glutamatergic dysfunction in OCD.  Neuropsychopharmacology 2005;30 (9) 1735- 1740PubMedGoogle ScholarCrossref
13.
Lafleur  DLPittenger  CKelmendi  BGardner  TWasylink  SMalison  RTSanacora  GKrystal  JHCoric  V N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.  Psychopharmacology (Berl) 2006;184 (2) 254- 256PubMedGoogle ScholarCrossref
14.
Chamberlain  SRFineberg  NABlackwell  ADClark  LRobbins  TWSahakian  BJ A neuropsychological comparison of obsessive-compulsive disorder and trichotillomania.  Neuropsychologia 2007;45 (4) 654- 662PubMedGoogle ScholarCrossref
15.
Grant  JEPotenza  MN Compulsive aspects of impulse-control disorders.  Psychiatr Clin North Am 2006;29 (2) 539- 551PubMedGoogle ScholarCrossref
16.
Swedo  SELeonard  HL Trichotillomania: an obsessive compulsive spectrum disorder?  Psychiatr Clin North Am 1992;15 (4) 777- 790PubMedGoogle Scholar
17.
Stein  DJSimeon  DCohen  LJHollander  E Trichotillomania and obsessive-compulsive disorder.  J Clin Psychiatry 1995;56 ((suppl 4)) 28- 34; discussion, 35PubMedGoogle Scholar
18.
Coric  VTaskiran  SPittenger  CWasylink  SMathalon  DHValentine  GSaksa  JWu  Y-TGueorguieva  RSanacora  GMalison  RTKrystal  JH Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.  Biol Psychiatry 2005;58 (5) 424- 428PubMedGoogle ScholarCrossref
19.
Odlaug  BLGrant  JE N-acetyl cysteine treatment of grooming disorders.  J Clin Psychopharmacol 2007;27 (2) 227- 229PubMedGoogle ScholarCrossref
20.
Coric  VKelmendi  BPittenger  CWasylink  SBloch  MHGreen  J Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with trichotillomania.  J Clin Psychiatry 2007;68 (1) 170- 171PubMedGoogle ScholarCrossref
21.
McFarland  KLapish  CCKalivas  PW Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior.  J Neurosci 2003;23 (8) 3531- 3537PubMedGoogle Scholar
22.
Baker  DAMcFarland  KLake  RWShen  HToda  SKalivas  PW N-acetyl cysteine-induced blockade of cocaine-induced reinstatement.  Ann N Y Acad Sci 2003;1003349- 351PubMedGoogle ScholarCrossref
23.
LaRowe  SDMardikian  PMalcolm  RMyrick  HKalivas  PMcFarland  KSaladin  MMcRae  ABrady  K Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals.  Am J Addict 2006;15 (1) 105- 110PubMedGoogle ScholarCrossref
24.
Kalivas  PWVolkow  NSeamans  J Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission.  Neuron 2005;45 (5) 647- 650PubMedGoogle ScholarCrossref
25.
Kalivas  PWVolkow  ND The neural basis of addiction: a pathology of motivation and choice.  Am J Psychiatry 2005;162 (8) 1403- 1413PubMedGoogle ScholarCrossref
26.
First  MBSpitzer  RLGibbon  MWilliams  JBW Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition (SCID-I/NP).  New York Biometrics Research, New York State Psychiatric Institute2002;
27.
Rothbaum  BONinan  PT The assessment of trichotillomania.  Behav Res Ther 1994;32 (6) 651- 662PubMedGoogle ScholarCrossref
28.
Christenson  GAMansueto  CS Trichotillomania: descriptive characteristics and phenomenology. Stein  DJChristianson  GAHollander  E Trichotillomania. Washington, DC American Psychiatric Press1999;1- 41Google Scholar
29.
Grant  JEKim  SWOdlaug  BL N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study.  Biol Psychiatry 2007;62 (6) 652- 657PubMedGoogle ScholarCrossref
30.
Mardikian  PNLaRowe  SDHedden  SKalivas  PWMalcolm  RJ An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study.  Prog Neuropsychopharmacol Biol Psychiatry 2007;31 (2) 389- 394PubMedGoogle ScholarCrossref
31.
Cavallini  LAlexandre  A Oral N-acetyl-cysteome increases the production of anti HIV chemokines in peripheral blood mononuclear cells.  Life Sci 2000;67 (2) 147- 154PubMedGoogle ScholarCrossref
32.
First  MBSpitzer  RLGibbon  MWilliams  JBW Structured Clinical Interview for DSM-IV-Patient Edition (SCID-I/P, Version 2.0).  New York Biometrics Research Department, New York State Psychiatric Institute1995;
33.
Keuthen  NJO'Sullivan  RLRicciardi  JNShera  DSavage  CRBorgmann  ASJenike  MABaer  L The Massachusetts General Hospital (MGH) Hair Pulling Scale, 1: development and factor analyses.  Psychother Psychosom 1995;64 (3-4) 141- 145PubMedGoogle ScholarCrossref
34.
Winchel  RMJones  JSMolcho  AParsons  BStanley  BStanley  M The Psychiatric Institute Trichotillomania Scale (PITS).  Psychopharmacol Bull 1992;28 (4) 463- 476PubMedGoogle Scholar
35.
Hamilton  M The assessment of anxiety states by rating.  Br J Med Psychol 1959;32 (1) 50- 55PubMedGoogle ScholarCrossref
36.
Hamilton  M A rating scale for depression.  J Neurol Neurosurg Psychiatry 1960;2356- 62PubMedGoogle ScholarCrossref
37.
Sheehan  DV The Anxiety Disease.  New York, NY Scribner1983;
38.
Frisch  MBCornell  JVillaneuva  M Clinical validation of the Quality of Life Inventory: a measure of life satisfaction for use in treatment planning and outcome assessment.  Psychol Assess 1993;4 (1) 92- 101Google ScholarCrossref
39.
O'Sullivan  RLKeuthen  NJHayday  CFRicciardi  JNButtolph  MLJenike  MABaer  L The Massachusetts General Hospital (MGH) Hairpulling Scale, 2: reliability and validity.  Psychother Psychosom 1995;64 (3-4) 146- 148PubMedGoogle ScholarCrossref
40.
Keuthen  NJFlessner  CAWoods  DWFranklin  MEStein  DJCashin  SETrichotillomania Learning Center Scientific Advisory Board, Factor analysis of the Massachusetts General Hospital Hairpulling Scale.  J Psychosom Res 2007;62 (6) 707- 709PubMedGoogle ScholarCrossref
41.
Stanley  MACohen  LJ Trichotillomania and obsessive-compulsive disorder. Stein  DJChristianson  GAHollander  E Trichotillomania. Washington, DC American Psychiatric Press1999;225- 261Google Scholar
42.
Diefenbach  GJTolin  DFHannan  SCrocetto  JWorhunsky  P Trichotillomania: impact on psychosocial functioning and quality of life.  Behav Res Ther 2005;43 (7) 869- 884PubMedGoogle ScholarCrossref
43.
Davison  ACHinkley  DV Bootstrap Methods and Their Application.  Cambridge, England Cambridge University Press1997;
44.
Guy  W ECDEU Assessment Manual for Psychopharmacology.  Rockville, MD National Institute of Mental Health1976;Publication (ADM) 76-338
45.
Jacobson  NSTruax  P Clinical significance: a statistical approach to defining meaningful change in psychotherapy research.  J Consult Clin Psychol 1991;59 (1) 12- 19PubMedGoogle ScholarCrossref
46.
Dougherty  DDLoh  RJenike  MAKeuthen  NJ Single modality versus dual modality treatment for trichotillomania: sertraline, behavioral therapy, or both?  J Clin Psychiatry 2006;67 (7) 1086- 1092PubMedGoogle ScholarCrossref
47.
LaRowe  SDMyrick  HHedden  SMardikian  PSaladin  MMcRae  ABrady  KKalivas  PWMalcolm  R Is cocaine desire reduced by N-acetylcysteine?  Am J Psychiatry 2007;164 (7) 1115- 1117PubMedGoogle ScholarCrossref
48.
van Minnen  AHoogduin  KAKeijsers  GPHellenbrand  IHendriks  GJ Treatment of trichotillomania with behavioral therapy or fluoxetine: a randomized, waiting-list controlled study.  Arch Gen Psychiatry 2003;60 (5) 517- 522PubMedGoogle ScholarCrossref
49.
Woods  DWWetterneck  CTFlessner  CA A controlled evaluation of acceptance and commitment therapy plus habit reversal for trichotillomania.  Behav Res Ther 2006;44 (5) 639- 656PubMedGoogle ScholarCrossref
50.
Keijsers  GPvan Minnen  AHoogduin  CAKlaassen  BNHendriks  MJTanis-Jacobs  J Behavioural treatment of trichotillomania: two-year follow-up results.  Behav Res Ther 2006;44 (3) 359- 370PubMedGoogle ScholarCrossref
51.
Mayer  MNoble  M N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro.  Proc Natl Acad Sci U S A 1994;91 (16) 7496- 7500PubMedGoogle ScholarCrossref
52.
Hart  AMTerenghi  GKellerth  JOWiberg  M Sensory neuroprotection, mitochondrial preservation, and therapeutic potential of n-acetyl-cysteine after nerve injury.  Neuroscience 2004;125 (1) 91- 101PubMedGoogle ScholarCrossref
53.
Han  DSen  CKRoy  SKobayashi  MSTritschler  HJPacker  L Protection against glutamate-induced cytotoxicity in C6 glial cells by thiol antioxidants.  Am J Physiol 1997;273 (5, pt 2) R1771- R1778PubMedGoogle Scholar
54.
Lochner  CHemmings  SMKinnear  CJNiehaus  DJNel  DGCorfield  VAMoolman-Smook  JCSeedat  SStein  OJ Cluster analysis of obsessive-compulsive spectrum disorders in patients with obsessive-compulsive disorder: clinical and genetic correlates.  Compr Psychiatry 2005;46 (1) 14- 19PubMedGoogle ScholarCrossref
55.
Flessner  CAConelea  CAWoods  DWFranklin  MEKeuthen  NJCashin  SE Styles of pulling in trichotillomania: exploring differences in symptom severity, phenomenology, and functional impact.  Behav Res Ther 2008;46 (3) 345- 357PubMedGoogle ScholarCrossref
56.
Flessner  CABusch  AMHeideman  PWWoods  DW Acceptance-enhanced behavior therapy (AEBT) for trichotillomania and chronic skin picking: exploring the effects of component sequencing.  Behav Modif 2008;32 (5) 579- 594PubMedGoogle ScholarCrossref
57.
Diefenbach  GJTolin  DFHannan  SMaltby  NCrocetto  J Group treatment for trichotillomania: behavior therapy versus supportive therapy.  Behav Ther 2006;37 (4) 353- 363PubMedGoogle ScholarCrossref
Original Article
July 2009

N-Acetylcysteine, a Glutamate Modulator, in the Treatment of Trichotillomania: A Double-blind, Placebo-Controlled Study

Author Affiliations

Author Affiliations: Department of Psychiatry, University of Minnesota School of Medicine, Minneapolis.

Arch Gen Psychiatry. 2009;66(7):756-763. doi:10.1001/archgenpsychiatry.2009.60
Abstract

Context  Trichotillomania is characterized by repetitive hair pulling that causes noticeable hair loss. Data on the pharmacologic treatment of trichotillomania are limited to conflicting studies of serotonergic medications. N-acetylcysteine, an amino acid, seems to restore the extracellular glutamate concentration in the nucleus accumbens and, therefore, offers promise in the reduction of compulsive behavior.

Objective  To determine the efficacy and tolerability of N-acetylcysteine in adults with trichotillomania.

Design  Twelve-week, double-blind, placebo-controlled trial.

Setting  Ambulatory care center.

Patients  Fifty individuals with trichotillomania (45 women and 5 men; mean [SD] age, 34.3 [12.1] years).

Interventions  N-acetylcysteine (dosing range, 1200-2400 mg/d) or placebo was administered for 12 weeks.

Main Outcome Measures  Patients were assessed using the Massachusetts General Hospital Hair Pulling Scale, the Clinical Global Impression scale, the Psychiatric Institute Trichotillomania Scale, and measures of depression, anxiety, and psychosocial functioning. Outcomes were examined using analysis of variance modeling analyses and linear regression in an intention-to-treat population.

Results  Patients assigned to receive N-acetylcysteine had significantly greater reductions in hair-pulling symptoms as measured using the Massachusetts General Hospital Hair Pulling Scale (P < .001) and the Psychiatric Institute Trichotillomania Scale (P = .001). Fifty-six percent of patients “much or very much improved” with N-acetylcysteine use compared with 16% taking placebo (P = .003). Significant improvement was initially noted after 9 weeks of treatment.

Conclusions  This study, the first to our knowledge that examines the efficacy of a glutamatergic agent in the treatment of trichotillomania, found that N-acetylcysteine demonstrated statistically significant reductions in trichotillomania symptoms. No adverse events occurred in the N-acetylcysteine group, and N-acetylcysteine was well tolerated. Pharmacologic modulation of the glutamate system may prove to be useful in the control of a range of compulsive behaviors.

Trial Registration  clinicaltrials.gov Identifier: NCT00354770.

×